With no race for the cure or celebrity endorsements, invasive fungal infections have gained notoriety by infecting and mutating in hospitals and communities worldwide. Yet even with the limelight, this crisis has only fueled new efforts to combat invasive and resistant fungal infections among drug developers. Exacerbated by extreme attrition in R&D and the departure of big pharma companies, developers and infectious disease experts are wondering who will fund the translation of bench discoveries into beside medicines, how investors/analyst are valuing a space with nearly dried up pipelines, and whether the battle can be won by treating or preventing.

Panelists will discuss these issues as well as share their thoughts on funding strategies and partnerships that may fuel excitement and dollars.

Ability Level: All

Session ID: 21217